Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Non-Malignant Chronic Pain

NCT00126763 is registered in ClinicalTrials.gov with ZARS Pharma Inc. as lead sponsor.

NCT NCT00126763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Non-Malignant Chronic Pain
Lead sponsor
ZARS Pharma Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2005
Completion date
December 31, 2006
Enrollment
105 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pain